로딩 중…
지수 로딩 중…
Anterogen.Co.,Ltd.
065660· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩25,000-1.38%
2026-06-19
Price Chart
Anterogen.Co.,Ltd.+22.55%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 250.15B KRW |
| Revenue | 8.06B KRW |
| Net Income | -689.1M KRW |
| Total Assets | 84.79B KRW |
| Net Assets | 83.83B KRW |
| Employees | 29 |
| Value | |
| P/B | 2.98x |
| P/S | 31.05x |
| FCF Yield | -0.45% |
| Profitability | |
| ROE | -0.82% |
| ROA | -0.81% |
| Op. Margin | -5.95% |
| Revenue Growth | 32.49% |
| Financial Health | |
| Debt Ratio | 101.14% |
| Total Debt | 0 KRW |
| FCF | -1.12B KRW |
| Cash | 1.68B KRW |
| Current Ratio | 63.40x |
| Performance | |
| 1Y Return | 22.55% |
| 1M Return | -18.17% |
| From 52W High | -59.55% |
| 1Y MDD | -57.84% |
| Trading | |
| Volume | 23,341 shares |
| Foreign Own. | 3.51% |
| Per Share | |
| EPS | -156 KRW |
| BPS | 8,378 KRW |
Company Info
Antrogen, established in 2000 and listed on KOSDAQ in 2016, is a specialized stem cell therapy bio-venture. In 2012, it gained the world's first marketing approval for Cupistem, an adipose-derived stem cell product for Crohn's fistula, and holds exclusive domestic sales rights for pulmonary hypertension treatments Remodulin and Tyvaso. Through its diverse disease pipeline, Antrogen is expanding its business and strengthening its competitive edge in rare and intractable disease treatments. It is headquartered in Geumcheon-gu, Seoul.